×

Potential board changes at Valeant

6:07 AM ET Thu, 28 April 2016

CNBC's Meg Tirrell reports on yesterday's Capitol Hill hearing on drug pricing where outgoing Valeant CEO Michael Pearson and activist investor Bill Ackman testified.